Potential anticancer agents. I. synthesis of isoxazole moiety containing quinazoline derivatives and preliminarily in vitro anticancer activity

Anti-Cancer Agents in Medicinal Chemistry

Volumn 15, Issue 1, 2015, Pages 131-136

  Yong, Jian Ping ^a   Lu, Can Zhong ^a   Wu, Xiaoyuan ^b  

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^b NONE

Author keywords

Anticancer activity; Isoxazole moiety; Quinazoline derivatives; Synthesis

Indexed keywords

2 CHLORO 6,7 DIMETHOXY 4 {[3 (2,4 DICHLORO PHENYL) ISOXAZOL 5 YL ] METHOXY} QUINAZOLINE; 2 CHLORO 6,7 DIMETHOXY 4 {[3 (4 CHLORO PHENYL) ISOXAZOL 5 YL ] METHOXY} QUINAZOLINE; 2 CHLORO 6,7 DIMETHOXY 4 [(3 P TOLYL ISOXAZOL 5 YL ) METHOXY ] QUINAZOLINE; 2 CHLORO 6,7 DIMETHOXY 4 [(3 PHENYL ISOXAZOL 5 YL ) METHOXY ] QUINAZOLINE; 2 CHLORO 6,7 DIMETHOXY 4 {[3 (2 CHLORO PHENYL) ISOXAZOL 5 YL ] METHOXY}QUINAZOLINE; 2 CHLORO6,7 DIMETHOXY 4 {[3 (4 BROMO PHENYL) ISOXAZOL 5 YL ] METHOXY} QUINAZOLINE; 2 CHOLORO 6,7 DIMETHOXY 4 {[3 (4 METHOXY PHENYL) ISOXAZOL 5 YL ] METHOXY QUINAZOLINE; 2 PHENYL 4 [(3 P TOLYL ISOXAZOL 5 YL ) METHOXY ] QUINAZOLINE; 2 PHENYL 4 [(3 PHENYL ISOXAZOL 5 YL ) METHOX ] QUINAZOLINE; 2 PHENYL 4 {[3 (2 CHLORO PHENYL) ISOXAZOL 5 YL ] METHOXY }QUINAZOLINE; 2 PHENYL 4 {[3 (2,4 DICHLORO PHENYL) ISOXAZOL 5 YL ] METHOXY } QUINAZOLINE; 2 PHENYL 4 {[3 (4 BROMO PHENYL) ISOXAZOL 5 YL ] METHOXY } QUINAZOLINE; 2 PHENYL 4 {[3 (4 CHLORO PHENYL) ISOXAZOL 5 YL ] METHOXY } QUINAZOLINE; 2 PHENYL 4 {[3 (4 METHOXY PHENYL) ISOXAZOL 5 YL ] METHOXY }QUINAZOLINE; ANTINEOPLASTIC AGENT; GEFITINIB; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; ISOXAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CARBON NUCLEAR MAGNETIC RESONANCE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HUMAN CELL; INFRARED SPECTROMETRY; LUNG CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; CHEMISTRY; DRUG SCREENING; HCT116 CELL LINE; MCF 7 CELL LINE; PROCEDURES; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HCT116 CELLS; HUMANS; ISOXAZOLES; MCF-7 CELLS; QUINAZOLINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84919687616     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520614666140812105445     Document Type: Article

References (25)

1. Ferlay, J.; Autier, P.; Boniol, M.; Heanue, M.; Colombet, M.; Boyle, P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol., 2007, 18, 581-592.
2. Soria, J.C.; Mok, T.S.; Cappuzzo, F.; Jänne, P.A. EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects. Cancer Treat. Rews., 2012, 38, 416-430.
3. Zhang, Y.; Wang, P.Y.; Hu, D.Y.; Jin, L.H.; Yang, S. Research progress on quinazoline derivatives with epidermal growth factor receptor inhibiting bioactivity. Chin. J. Org. Chem., 2012, 32, 444-461.
4. Li, D.D.; Hou, Y.P.; Wang, W.; Zhu, H.L. Exploration of chemical space based on 4-nilinoquinazoline. Curr. Med. Chem., 2012, 19, 871-892.
5. Chen, J.H.; Luo, Y.Z.; Wang, W.; Zhou, W.W.; Wen, X.P. A phase III study on icotinib hydrochloride for non-small cell lung cancer. Anti-tumor Pharm., 2011, 1, 441-443.
6. Gu, A.Q.; Shi, C. L.; Xiong, L.W.; Chu, T.Q.; Jun, P.; Han, B.H. Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer. Chin. J. Cancer Res., 2013, 25, 90-94.
7. Hamama, W.S.; Ibrahim, M.E.; Zoorob, H.H. Advances in the chemistry of aminoisoxazole. Synth. Commun., 2013, 43, 2393-2440.
8. Kumbhare, R.M.; Kosurkar, U.B.; Ramaiah, M.J.; Dadmal, T.L.; Pushapavalli, S.N.C.V.L.; Pal-Bhadra, M. Syntheisis and biological evaluation of novel triazoles and isoxazoles linked 2-phenyl benzothiazole as potential anticancer agents. Bioorg. Med. Chem. Lett., 2012, 22, 5424-54227.
9. Song, J.H. Lee, K.H.; Kim, D.R.; J.M. Kim, Lee, S.; Shim, J.S.; Kim, D.S.; Min, K.H. Synthesis and bioevaluation of 4, 5, 6, 7-tetrahydrobenzo[d]isoxazole derivatives as melanogensis inhibitors. Bull. Korean Chem. Soc., 2014, 35, 2, 666-668.
10. Gao, Z.L.; Hurst, W.J.; Czechtizky, W.; Hall, D.; Moindrot, N.; Nagorny, R.; Pichat, P.; Stefany, D.; Hendrix, J.A.; George, P.G. Selenium nanoparticles induced membrane bio-mechanical property changes in MCF-7 cells by disturbing membrane molecules and Factin. Bioorg. Med. Chem. Lett., 2013, 23(23), 6296-6273.
11. Ostacolo, G.; Ambrosino, P.; Russo, R.; Monte, M.L.; Soldovieri, M.V.; Laneri, S.; Sacchi, A.; Visoli, G.; Taglialatela, M.; Calignano, A. Isoxazole derivatives as potent transient receptor potential melastatin type 8 (TRPM8) agonists. Eur. J. Med. Chem., 2013, 69, 659-669.
12. North, E.J.; Scherman, M.S.; Bruhn, D.F.; Scarborough, J.S.; Maddox, M.M.; Jones, V.; Grzegorzewicz, A.; Yang, L.; Hess, T.; Morisseau, C.; Jackson, M.; McNeil, M.R.; Lee, R.E. Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties. Bioorg, Med. Chem., 2013, 21(9), 2587-2599.
13. Kankala, S.; Kankala, R.K.; Gundepaka, P.; Thota, N.; Nerella, S.; Gangula, M.R.; Guguloth, H.; Kagga, M.; Vadde, R.; Vasam, C.S. Regioselective synthesis of isoxazole–mercaptobenzimidazole hybrids and their in vivo analgesic and anti-inflammatory activity studies. Bioorg. Med. Chem. Lett., 2013, 23(5), 1306-1309.
14. Bargiotti, A.; Musso, L.; Dallavalle, S.; Merlini, L.; Gallo, G.; Ciacci, A.; Giannini, G.; Cabri, W.; Penco, S.; Vesci, L.; Castorina, M.; Milazzo, F.M.; Cervoni, M.L.; Barbarino, M.; Pisano, C.; Giommarelli, C.; Zuco, V.; Cesare, M.D.; Zunino, F. Isoxazolo (aza)naphthoquinones: A new class of cytotoxic Hsp90 inhibitors. Eur. J. Med. Chem., 2013, 53, 64-75.
15. Wang, J.W.; Xu, W.R.; Yong, J.P.; Tang, L.D.; Zhang, S.J.; Liu, L.J.; Wang, Y.L.; Ren, X.W. Glycyrrhetinic acid-30-amide derivatives and their use. U.S. Patent 7, 790, 759, September 7, 2010.
16. Jin, R.F.; Liu, J.; Zhang, J.X.; Tian, Y.H. Effect of glycyrrhetinic acid and its derivative TY501 on the proliferation of murine macrophae RAW 264.7. Drug Evalu. Res., 2011, 34, 255-257.
17. Cui, L.P.; Wang, Y.L.; Zhang, S.J.; Fu, H.X.; Xu, W.R.; Tang, L.D.; Wang, J.W. Effects of glycyrrhetinic acid derivative on renal injury of rats. Chin. Tradit. Herb. Drugs., 2011, 42, 1177-1179.
18. Sambasiva, P.S.; Rao, C.; Kurumurthy, B.; Veeraswamy, Y.; Poornachandra, C.G.; Kumar, B. Narsaiah, Synthesis of novel 5-(3-alkylquinolin-2-yl)-3-aryl isoxazole derivatives and their cytotoxic activity. Bioorg. Med. Chem. Lett., 2014, 24, 1349-1351.
19. Yong, J.P.; Lu, C.Z.; Wu, X.Y. Synthesis of isoxazole moiety containing ferrocene derivatives and preliminarily in vitro anticancer activity. Med. Chem. Cumm., 2014, 7, 968-972.
20. Liu, L.J.; Yong, J.P.; Dai, X.J.; Jia, J.; Wang, X.Z.; Wang, J.W. Synthesis of novel isoxazole contained glycyrrhetinic acid derivatives. Chem. J. Chin. Univ., 2006, 27, 1669-1672.
21. Huang, X.F.; Wang, L.Z.; Tang, L.; Lu, Y.X.; Wang, F.; Song, G. Q.; Ruan, B.F. Synthesis, characterization and antitumor activity of novel ferrocene derivatives containing pyrazolyl-moiety. J. Organomet. Chem., 2014, 749, 157-162.
22. Chen, X.Y.; Plasencia, C.; Hou, Y.P.; Neamati, N. Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J. Med. Chem., 2005, 48(4), 1098-1106.
23. El-Sherbeny, M.A.; Abdel-Aziz, A.A.M.; Ahmed, M. A. Synthesis and antitumor evaluation of novel diarylsulfonylurea derivatives: Molecular modeling applications. Eur. J. Med. Chem., 2010, 45, 689-697.
24. Altman, E.P. Tetrazolium salts and formazans. Prog. Histochem. Cytochem., 1976, 9, 1-56.
25. Alley, M.C.; Scudiero, D.A.; Monks, A.; Hursey, M.L.; Czerwinski, M.J.; Fine, D.L.; Abbott, B.J.; Mayo, J.G.; Shoemaker, R.H.; Boyd, M.R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res., 1988, 48, 589-601.